Otrivine Décongestionnant (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. When sprayed into the nose, it binds to alpha receptors on the blood vessels of the nasal mucosa, causing vasoconstriction. This reduces swelling, opens the airway, and improves breathing.

The appropriate dose is determined by a healthcare professional based on the patient’s age, condition, and response. Typically, one or two sprays per nostril are used, but the prescriber’s instructions should always be followed.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using the product to weigh potential benefits against risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Otrivine Décongestionnant contains Xylometazoline, which has a rapid onset of action and a duration of about 8‑12 hours. Compared with phenylephrine or oxymetazoline, Xylometazoline offers similar efficacy but may have a slightly lower incidence of rebound congestion when used as directed.

Store the nasal spray at temperatures below 25 °C (77 °F). Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

The product is administered as a nasal spray. The user gently inserts the tip into a nostril, closes the opposite nostril, and presses the pump to deliver the recommended number of sprays. The spray should be directed toward the outer wall of the nostril, not the septum.

Serious risks include rebound nasal congestion if used for more than three consecutive days, elevated blood pressure, and rare severe allergic reactions such as anaphylaxis. Patients experiencing these symptoms should discontinue use and seek medical attention promptly.

Individuals with known hypersensitivity to Xylometazoline or any component of the formulation should avoid the product. It is also contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or those with severe hypertension unless directed by a physician.